Perkins Seminar with Assoc. Prof Fiona Simpson

About Us
About Perkins

Since 1998, the Perkins has grown to become one of the nation's leading adult medical research centres, where a close-knit team of more than 450 research and clinical staff work together to defeat the major diseases that impact our community.
Research
Research

Perkins researchers focus on some of the major diseases that affect our community. In particular we focus on cancer, diabetes, heart disease and neuromuscular diseases.
Support the Perkins
Support the Perkins

Your support will help us to deliver a healthier future through medical breakthroughs, new treatments and fostering the next generation of scientific talent.
Get Involved
Get Involved

You can support Perkins work in many different ways. From participating in an event, to attending a workshop in the BioDiscovery Centre, to volunteering your time, or supporting our research, we welcome your involvement.
Donate

Apr 27

Home > Perkins Seminar with Assoc. Prof Fiona Simpson > Perkins Seminar with Assoc. Prof Fiona Simpson

Join us to hear from Associate Professor Fiona Simpson, Research Fellow at the Queensland Head and Neck Research Centre.

Her topic: Traffic calming measures: reversing cancer resistance and controlling immune cell activity.

A light lunch will be served in the foyer following A/Prof Simpson’s presentation.

Fiona completed her PhD on cellular trafficking at the University of Cambridge, UK. She was then a Wellcome Trust Prize Post-doctoral fellow at The Scripps Research Institute, La Jolla, working on trafficking and endocytosis of RTKs. Fiona is currently a Fellow of the Queensland Head and Neck Cancer Centre.

The Simpson lab research program is focused directly on the translation of research findings into new cancer therapies and has generated a novel method for antibody-mediated cancer therapy and associated companion diagnostic methods which are covered by three international patent applications and published in Cell (March 2020) and Cell Press STAR Protocols (Aug 2020). Fiona was the lead scientific investigator on a Phase I proof of concept study of the novel therapy in head and neck cancer (HREC/15/ QPAH/48) and the Lead scientific Investigator on Phase IB dose escalation trail (CESTEM-1), now completed.